Clinical trials: Neurotrophic Keratitis
Neurotrophic Keratopathy
Efficacy and Safety of Topical Insulin for Neurotrophic Corneal Ulcers
To evaluate Safety and efficacy of topical insulin in treatment of neurotrophic corneal ulcers
- Trial name
- NCT06331910
- Testing
- insulin eye drops
- Volunteers
- 14 people
- Sponsor
- Assiut University
Neurotrophic Keratopathy
A Clinical Trial to Asses Efficacy and Safety of Cord Blood Eye Drops in Neurotrophic Keratopathy
This is a multicenter, randomized, open-label, two-arms phase I/II, clinical trial, in which 42 patients will be enrolled with the principal objective to evaluate the efficacy through changes in lesion size and, secondary, to…
- Trial name
- NCT03084861
- Testing
- Cord Blood Eye Drops, Conventional treatment
- Where
- 10 sites in Spain
- Volunteers
- 9 people
- Sponsor
- Banc de Sang i Teixits
Neurotrophic Keratopathy
Assessment of the Safety and Efficacy Study of RGN-259 Ophthalmic Solutions for Neurotrophic Keratopathy : SEER-1
The objective of this study is to assess the safety and efficacy of RGN-259 Ophthalmic Solution compared to placebo for the treatment of NK.
- Trial name
- NCT02600429
- Testing
- RGN-259
- Where
- 11 sites in United States
- Volunteers
- 18 people
- Sponsor
- ReGenTree, LLC
Neurotrophic Keratopathy
Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2
The objective of this study is to compare the safety and efficacy of RGN-259 to placebo for the treatment of Neurotrophic Keratopathy (NK)
- Trial name
- NCT05555589
- Testing
- RGN-259
- Where
- 36 sites in United States, Italy and 2 more
- Volunteers
- 70 people
- Sponsor
- ReGenTree, LLC
Neurotrophic Keratitis
Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects
This study will enroll subjects with stage 2 or 3 neurotrophic keratitis. Subjects will be randomized in a 1:1 ratio to the CSB-001 investigational treatment arm or vehicle control arm.
- Trial name
- NCT04909450
- Testing
- CSB-001 Ophthalmic Solution 0.1%, Vehicle Control
- Where
- 48 sites in United States, Canada
- Volunteers
- 131 people
- Sponsor
- Claris Biotherapeutics, Inc.
Neurotrophic Corneal Ulcer, Neurotrophic Keratitis
Corneal Neurotization as a Treatment for Neurotrophic Keratopathy
The purpose of this study is to assess the efficacy of sural nerve transfer and cadaveric nerve graft to re-establish corneal sensation in patients with neurotrophic keratopathy.
- Conditions
- Neurotrophic Corneal Ulcer, Neurotrophic Keratitis, Cranial Nerve V Diseases
- Trial name
- NCT05809245
- Testing
- Corneal neurotization
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Stanford University
Neurotrophic Keratitis, Keratitis
Evaluation of Safety and Efficacy of rhNGF in Patients With Stage 2 and 3 Neurotrophic Keratitis.
This study is aimed at assessing the safety and the efficacy of two dose regimens of recombinant human nerve growth factor (rhNGF) eye drops solution compared to vehicle for inducing a complete healing of stage 2 (persistent…
- Conditions
- Neurotrophic Keratitis, Keratitis, Corneal Ulcer
- Trial name
- REPARO (NCT01756456)
- Testing
- rhNGF 10 μg/ml, rhNGF 20 μg/ml, vehicle
- Where
- 34 sites in France, Germany and 4 more
- Volunteers
- 174 people
- Sponsor
- Dompé Farmaceutici S.p.A
Neurotrophic Keratitis
A Phase II Study of STSP-0902 Ophthalmic Solution in Patients With Neurotrophic Keratitis
This is a Phase II, double-blind, placebo-controlled study to evaluate the safety and efficacy of STSP-0902 ophthalmic solution in patients with neurotrophic keratitis (NK).
- Trial name
- NCT06975748
- Testing
- STSP-0902 ophthalmic solution
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Staidson (Beijing) Biopharmaceuticals Co., Ltd
Neurotrophic Keratitis
Assessment of the Initial Efficacy and Safety of BRM424 Ophthalmic Solutions in Patients With Neurotrophic Keratitis
The objective of this study is to obtain initial efficacy of BRM424 in patients with Stage 2 and Stage 3 NK and evaluate safety and tolerability.
- Trial name
- NCT05927428
- Testing
- BRM424 Ophthalmic Solution - Dose1, BRM424 Ophthalmic Solution - Dose2
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- BRIM Biotechnology Inc.
Neurotrophic Keratitis
Nerve Growth Factor for the Treatment of Cornea Disease
To determine the efficacy and safety of nerve growth factor in the treatment of limbal stem cell deficiency (LSCD) associated with neurotrophic cornea.
- Trial name
- NCT04552730
- Testing
- Cenegermin-Bkbj
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Stanford University
Neurotrophic Keratitis
DEFENDO Long Term Follow-up Study in Stage 1 NK Patients
Primary Objective To evaluate the long-term safety and efficacy (healing) of OXERVATE® 0.002% (20 mcg/mL) cenegermin-bkbj ophthalmic solution in Stage 1 neurotrophic keratitis (NK) patients who enrolled in the DEFENDO study.
- Trial name
- NCT05552261
- Testing
- Cenegemin in the DEFENDO Study
- Where
- 4 sites in United States
- Volunteers
- 24 people
- Sponsor
- Dompé Farmaceutici S.p.A
Neurotrophic Keratitis
Corneal Nerves After Treatment With Cenegermin
Neurotrophic keratopathy (NK) is a condition in which patients have fewer or complete absence of nerves in the cornea, characterized by the reduced or absent corneal sensation.
- Trial name
- NCT04627571
- Testing
- Cenegermin Ophthalmic Solution [Oxervate]
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of California, Los Angeles
Neurotrophic Keratitis
A Multicenter, Randomized, Vehicle-Controlled, Double-Masked to Open-Label Study to Evaluate the Safety and Efficacy of Lacripep in Subjects With Neurotrophic Keratitis
Objective: To evaluate the safety of Lacripep 4 μM Ophthalmic Solution and its effect on the ocular surface, visual function, corneal sensitivity, and quality of life of subjects with Stage 1 NK.
- Trial name
- NCT07568730
- Testing
- Lacripep, Vehicle Ophthalmic Solution
- Where
- 6 sites in United States
- Volunteers
- 54 people
- Sponsor
- TearSolutions, Inc.
Neurotrophic Keratitis
Topical Insulin Drops for the Treatment of Neurotrophic Keratopathy.
Many diseases can affect corneal nerves. Corneas that lack normal sensation are considered neurotrophic. Neurotrophic corneas are predisposed to persistent epithelial defects, recurrent erosions, and corneal ulcers.
- Trial name
- NCT05321251
- Testing
- Insulin, Tarsorrhaphy
- Where
- 6 sites in Canada
- Sponsor
- University of Alberta
Diabetic Retinopathy, Neurotrophic Keratitis
An Investigator-Initiated Study to Assess the Association of Diabetic Retinopathy Severity Scale (DRSS) With Level of Decreased Corneal Sensitivity
Evaluate the association between level of decreased corneal sensitivity and diabetic retinopathy severity scale
- Trial name
- Assess (NCT05566717)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Medical Center Ophthalmology Associates
Keratitis, Corneal Ulcer
Efficacy and Safety Assessment of T4020 Versus Vehicule in Patients With Chronic Neurotrophic Keratitis or Corneal Ulcer
The purpose of this study is to assess the efficacy and safety of T4020 versus vehicle.
- Trial name
- NCT01794312
- Testing
- T4020, Vehicle
- Where
- France
- Volunteers
- 152 people
- Sponsor
- Laboratoires Thea
Neurotrophic Keratitis
Corneal Neurotization vs. Cenergermin for Neurotrophic Keratitis: A Pilot Study
This pilot study evaluates the feasibility and outcomes of two treatment approaches for corneal sensory dysfunction due to neurotrophic keratitis (NK): corneal neurotization surgery and topical Cenergermin (Oxervate).
- Trial name
- NCT07073729
- Testing
- Corneal Neurotization, Cenergermin
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Neurotrophic Keratitis, Neurotrophic Keratopathy
Open-label Trial to Evaluate Efficacy and Safety of rhNGF on Corneal Thickness Via AS-OCT in Neurotrophic Keratitis
Primary Objective: To assess the efficacy of cenegermin-bkbj (20 mcg/mL) ophthalmic solution on overall corneal thickness via AS-OCT in patients with stage 3 neurotrophic keratitis with respect to change from baseline at weeks 4…
- Conditions
- Neurotrophic Keratitis, Neurotrophic Keratopathy, Corneal Ulcer
- Trial name
- IMAGO (NCT06411145)
- Testing
- OXERVATE® 0.002%
- Sponsor
- Dompé Farmaceutici S.p.A
Rare Diseases, Aniridia
Validation of Human Drugs Target of Repurposed Drugs and Novel Therapies
The cross-sectional observational clinical study related to rare eye diseases is a multi-center study in which the hypothesis is that neurokinin 1 receptor and/or substance P expression is increased in REDs associated with…
- Conditions
- Rare Diseases, Aniridia, Neurotrophic Keratopathy, Limbal Stem Cell Deficiency
- Trial name
- NCT06412718
- Volunteers
- 274 people, healthy volunteers welcome
- Sponsor
- IRCCS Ospedale San Raffaele
Neurotrophic Keratitis
Evaluation of Efficacy of 20 µg/ml rhNGF New Formulation (With Anti-oxidant) in Patients With Stage 2 and 3 NK
The primary objective of this study is to evaluate the efficacy of 20 µg/ml 6 times a day of rhNGF eye drops solution (formulation containing anti-oxidant) compared to vehicle (formulation containing anti-oxidant) given 6 times a…
- Trial name
- NCT02227147
- Testing
- rhNGF 20µg/ml
- Where
- 12 sites in United States
- Volunteers
- 48 people
- Sponsor
- Dompé Farmaceutici S.p.A